Literature DB >> 17303785

Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.

Francesca Porcellati1, Paolo Rossetti, Natalia Busciantella Ricci, Simone Pampanelli, Elisabetta Torlone, Susana Hernandez Campos, Anna Marinelli Andreoli, Geremia B Bolli, Carmine G Fanelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17303785     DOI： 10.2337/dc06-2208

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  12 in total

Review 1.  Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.

Authors:  Israel Hartman
Journal:  Clin Med Res       Date:  2008-09-18

Review 2.  Insulin analogues in type 1 diabetes mellitus: getting better all the time.

Authors:  Chantal Mathieu; Pieter Gillard; Katrien Benhalima
Journal:  Nat Rev Endocrinol       Date:  2017-04-21       Impact factor: 43.330

3.  International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.

Authors:  Geremia B Bolli; Larry C Deeb; Satish K Garg; John L Leahy; Roger S Mazze; David R Owens; Matthew C Riddle; Phil Southerland; Ellie S Strock
Journal:  Diabetes Technol Ther       Date:  2011-09       Impact factor: 6.118

4.  The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back.

Authors:  S G H A Swinnen; F Holleman; J H DeVries
Journal:  Diabetologia       Date:  2008-08-01       Impact factor: 10.122

5.  Dose-response effects of insulin glargine in type 2 diabetes.

Authors:  Zhihui Wang; Maka S Hedrington; Nino Gogitidze Joy; Vanessa J Briscoe; M Antoinette Richardson; Lisa Younk; Wendell Nicholson; Donna B Tate; Stephen N Davis
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 17.152

Review 6.  New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations.

Authors:  Paris Roach
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 7.  The evolution of insulin glargine and its continuing contribution to diabetes care.

Authors:  Rolf Hilgenfeld; Gerhard Seipke; Harald Berchtold; David R Owens
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

8.  Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.

Authors:  Helle Linnebjerg; Eric Chen Quin Lam; Xin Zhang; Mary E Seger; David Coutant; Laiyi Chua; Christoph Kapitza; Tim Heise
Journal:  Diabetes Obes Metab       Date:  2016-09-08       Impact factor: 6.577

Review 9.  Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.

Authors:  Tim Heise; Chantal Mathieu
Journal:  Diabetes Obes Metab       Date:  2016-09-26       Impact factor: 6.577

10.  Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.

Authors:  Geremia B Bolli; Annke D Hahn; Ronald Schmidt; Tanja Eisenblaetter; Raphael Dahmen; Tim Heise; Reinhard H A Becker
Journal:  Diabetes Care       Date:  2012-10-23       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.